Company: BIAF
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001493152-25-008471
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 1.01
Chunk 2
---
 Company in any U. S. stock exchange during such six (6) month period, and (b) if the Company, within twelve (12) months after the
Closing Date, effects a sale of any securities or warrant inducement with an investor that the Financial Advisor introduced to the Company
by direct meeting or presentation, the Company paid to the Financial Advisor the same cash discount and issued to the Financial
Advisor warrants exercisable for such number of shares equal to 3.0% of the securities issued in such offering upon the completion of
such transaction.

Terms
of the New Warrants

The
New Warrants have an exercise price of $0.85 per share, subject to adjustment as provided in the New Warrants, will beexercisable
at any time on or after the date on which the Company receives stockholder approval of the exercisability of the New Warrants and the
issuance of the New Warrant Shares upon exercise thereof (the “ Stockholder Approval Date”) and have a term of exercise of
five (5) years from the Stockholder Approval Date.

If
at any time after the later of (i) the six-month anniversary of the Closing Date, and (ii) the Stockholder Approval Date, a registration
statement registering the issuance of the New Warrant Shares under the Securities Act is not effective or available, the holder may,
in its sole discretion, elect to exercise the New Warrants through a cashless exercise, in which case the holder would receive upon such
exercise the net number of shares of Common Stock determined according to the formula set forth in the New Warrants.

The
exercise price of the New Warrants, and the number of New Warrant Shares, are subject to adjustment in the event of any stock
dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the New Warrants. The
Company may also at any time during the term of the New Warrants, subject to the prior written consent of the holder, voluntarily reduce
the then current exercise price to any amount and for any period of time, subject to the rules and regulations of Nasdaq.

A
holder will not have the right to exercise any portion of the New Warrants if the holder (together with its affiliates) would beneficially
own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after